Form 4: Recursion Pharma CEO Sells Shares, Converts Stock

Recursion Pharmaceuticals CEO Christopher Gibson reported the sale of 100,000 Class A shares and conversion of Class B shares, all under a pre-arranged 10b5-1 plan.

Summary

• Christopher Gibson, Chief Executive Officer and Director of RECURSION PHARMACEUTICALS, INC. (RXRX), reported several transactions on September 10, 2025.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
• Gibson converted 120,000 shares of Class B Common Stock into Class A Common Stock.
• He subsequently sold 100,000 shares of Class A Common Stock at a price of $4.71 per share.
• An additional 20,000 shares of Class A Common Stock were disposed of via a bona-fide gift, which involved an automatic conversion from Class B Common Stock.
• Following these transactions, Gibson directly holds 954,229 shares of Class A Common Stock.
• He also directly holds 5,253,034 shares of Class B Common Stock, which are convertible into Class A Common Stock on a one-for-one basis.
• Indirect holdings of Class B Common Stock include 386,000 shares through LAHWRAN-3 LLC, 388,000 shares through LAHWRAN-4 LLC, and 50,000 shares through the Gibson Family Trust, where Gibson serves as a member, manager, or trustee.
• Gibson holds various stock options to purchase Class A Common Stock with exercise prices ranging from $2.48 to $11.40, and expiration dates between December 30, 2030, and February 3, 2035.

Sentiment

Score: 5

Explanation: The transactions are part of a pre-arranged 10b5-1 plan, which suggests they are not based on new, material non-public information. While insider selling can sometimes be viewed negatively, the planned nature mitigates immediate concerns, leading to a neutral sentiment.

Positives

• The reported transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating that the sales were scheduled in advance and not based on new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, as it reduces the insider's direct equity stake.
• The sale price of $4.71 per share is noted.

Future Outlook

This filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity specific to Recursion Pharmaceuticals and its CEO. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• Disposal of 20,000 Class A Common Stock via a bona-fide gift.
• Indirect beneficial ownership of Class B Common Stock through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, where the reporting person is a member, manager, or trustee.

Stakeholder Impact

• Shareholders may note the reduction in direct equity holdings by the CEO, though the pre-planned nature of the sale lessens the immediate negative implication.
• The gift transaction represents a transfer of wealth from the reporting person.

Key Dates

Recommendation

The reported transactions are routine for an insider with a pre-arranged 10b5-1 trading plan. While a sale by a CEO is always noted, the planned nature suggests it is for personal financial management rather than a signal about the company's immediate prospects. Investors should monitor future filings and company performance, but this specific Form 4 does not provide a strong signal for a buy or sell action.

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Stock Sale, CEO, Christopher Gibson, 10b5-1 Plan, Biotechnology, Pharmaceutical, Equity Transaction, Share Disposal, Corporate Governance